The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- 05 Jun 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.
- 05 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2020.
- 24 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.